Idoxifene
Idoxifene
Idoxifene (pronounced: eye-DOX-ee-feen) is a Selective Estrogen Receptor Modulator (SERM) that was under development for potential use in the treatment of breast cancer and osteoporosis. However, its development was discontinued due to unfavorable clinical trial results.
Etymology
The term 'Idoxifene' is derived from the chemical name of the compound, which is 2-(4-[[2-(1-piperidinyl)ethoxy]methyl]phenoxy)-6-4-(2-pyridinyl)-1-piperazinyl-1H-benzimidazole. The 'Idoxi-' prefix is a contraction of the chemical name, while '-fene' is a common suffix used in the names of SERMs.
Related Terms
- Selective Estrogen Receptor Modulator (SERM): A type of drug that acts on the estrogen receptor, a type of protein found in various tissues including the breast and bone. SERMs can have both estrogenic and antiestrogenic effects, depending on the tissue.
- Breast Cancer: A type of cancer that forms in the cells of the breasts. It is the most common cancer in women worldwide.
- Osteoporosis: A condition characterized by a decrease in the density of bone, decreasing its strength and resulting in fragile bones.
- Clinical Trial: A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
External links
- Medical encyclopedia article on Idoxifene
- Wikipedia's article - Idoxifene
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski